tirzepatide diabetes prevention Shows Substantial Weight Loss for Patients With Type 1 Tirzepatide is a modern injectable

What they did: Multiple preclinical models (mice, rats) evaluated the combination AOD-9604 + GLP-1 agonist (Semaglutide or Liraglutide)

& Nau, C

This means it acts like a hormone involved in appetite, fullness, blood sugar control, and digestion

With its dual mechanism of action, it mimics natural incretin hormones to regulate blood sugar levels and reduce food intake, providing a comprehensive approach to managing these chronic conditions

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

This provides additional support and guidance to help you maintain your weight loss